Treatment response following dupilumab treatment in one DDEB patient
Published: 4 August 2023| Version 1 | DOI: 10.17632/p4y7t4248w.1
Contributor:
Wilson Jr AalaDescription
Mendeley supplemental figure 3. Patient-reported VAS for itch was comparatively lower after 12 weeks of dupilumab treatment (VAS=4) relative to pre-treatment (VAS=8). The number and size of active lesions in the arms and legs were also visibly reduced.
Files
Steps to reproduce
Dupilumab was given subcutaneously at a loading dose of 600 mg followed by 300 mg biweekly for a total of 12 weeks in one of the six DDEB patients. Visual analog score (VAS) for itch was obtained at four-week intervals.
Institutions
National Cheng Kung University
Categories
Dermatology